Corporate News

Key highlights

Filter

Period

Filter by

recent search

Showing: 105 of 17 Corporate News

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook
Capital Markets Day 2023 – Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

PARIS, FRANCE, 7 December 2023 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K.


Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases
Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases

PARIS, FRANCE, 17 May 2023 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from its growing rare disease portfolio will be presented at the 55th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN),…


Ipsen completes acquisition of Albireo,  expanding the scope of its Rare Disease portfolio
Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio

PARIS, FRANCE, 3 March 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced it has completed the acquisition of Albireo Pharma, Inc., a leading innovator in bile-acid modulators to treat rare liver conditions. The acquisition enriches Ipsen’s Rare Disease portfolio, with…


Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases
Ipsen to acquire Albireo accelerating growth in rare disease with treatments for several pediatric liver diseases

PARIS, FRANCE & BOSTON, U.S., 09 January 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) and Albireo (Nasdaq: ALBO) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Albireo, a leading innovator in bile-acid modulators…


Ipsen completes acquisition of Epizyme expanding its portfolio in oncology
Ipsen completes acquisition of Epizyme expanding its portfolio in oncology

PARIS, FRANCE, 12 August 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced the closing of the definitive merger agreement under which Ipsen has acquired Epizyme, Inc. (Epizyme). Pursuant to the transaction, Ipsen acquires all outstanding shares of Epizyme for $1.45…


Your dedicated contacts